OLIPASS Corporation (244460.KQ)
- Previous Close
1,651.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
1,651.00 - 1,651.00 - 52 Week Range
1,568.00 - 9,250.00 - Volume
0 - Avg. Volume
258,744 - Market Cap (intraday)
8.936B - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD/DR; HIF-1a for chemo/radio-sensitizer treatment; Dystrophin for the treatment of duchenne muscular disease; and PTP1B for the treatment of type II diabetes. It is also involved in the development of CTLA4 immuno-oncology, PD1 immuno-oncology, and NOX4 fibrosis. In addition, the company engages in the collaborative research and development with OliPass Cosmeceuticals for life style management solutions, as well as Target X1 and Target X2. OLIPASS Corporation was founded in 2006 and is headquartered in Yongin-si, South Korea.
www.olipass.comRecent News: 244460.KQ
View MorePerformance Overview: 244460.KQ
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 244460.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 244460.KQ
View MoreValuation Measures
Market Cap
8.94B
Enterprise Value
13.95B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.51
Price/Book (mrq)
0.76
Enterprise Value/Revenue
18.46
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.59%
Return on Equity (ttm)
-216.38%
Revenue (ttm)
5.25B
Net Income Avi to Common (ttm)
-16.72B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
7.97B
Total Debt/Equity (mrq)
211.92%
Levered Free Cash Flow (ttm)
-6B